India markets open in 6 hours 21 minutes
  • BSE SENSEX

    52,773.05
    +221.52 (+0.42%)
     
  • Nifty 50

    15,869.25
    +57.40 (+0.36%)
     
  • Dow

    34,299.33
    -94.42 (-0.27%)
     
  • Nasdaq

    14,072.86
    -101.29 (-0.71%)
     
  • BTC-INR

    2,932,214.00
    -4,187.75 (-0.14%)
     
  • CMC Crypto 200

    995.05
    -15.56 (-1.54%)
     
  • Hang Seng

    28,638.53
    -203.60 (-0.71%)
     
  • Nikkei

    29,441.30
    +279.50 (+0.96%)
     
  • EUR/INR

    88.9780
    +0.2683 (+0.30%)
     
  • GBP/INR

    103.2759
    +0.0637 (+0.06%)
     
  • AED/INR

    19.9260
    +0.0470 (+0.24%)
     
  • INR/JPY

    1.4976
    -0.0037 (-0.25%)
     
  • SGD/INR

    55.2680
    +0.0860 (+0.16%)
     

Akoya to Report First Quarter 2021 Financial Results on May 18, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 562-0146 for domestic callers or (661) 567-1226 for international callers, followed by Conference ID: 7824008. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@akoyabio.com

Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com